You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

KANUMA Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: KANUMA
High Confidence Patents:0
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for KANUMA
Recent Clinical Trials for KANUMA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Alexion PharmaceuticalsPhase 3
Alexion PharmaceuticalsPhase 2/Phase 3
Alexion PharmaceuticalsPhase 1/Phase 2

See all KANUMA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for KANUMA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for KANUMA Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for KANUMA Derived from Patent Text Search

These patents were obtained by searching patent claims

Market Dynamics and Financial Trajectory for the Biologic Drug: KANUMA

Introduction

KANUMA, developed by Alexion Pharmaceuticals, is a biologic drug used to treat lysosomal acid lipase deficiency (LAL-D), a rare genetic disorder. Understanding the market dynamics and financial trajectory of KANUMA is crucial for stakeholders, including investors, healthcare providers, and patients.

Approval and Launch

KANUMA was approved by the U.S. Food and Drug Administration (FDA) in December 2015 for the treatment of LAL-D. Its launch marked a significant milestone in the treatment of this rare disease, providing a much-needed therapeutic option for patients[5].

Market Position

KANUMA operates in the niche market of rare diseases, specifically targeting LAL-D. This market is characterized by high unmet medical needs and limited competition, which can lead to premium pricing and significant revenue potential.

Revenue Performance

In the fourth quarter of 2020, KANUMA net product sales were $117.9 million, representing a 5% increase compared to the same period in 2019. This modest growth indicates a stable market presence and ongoing demand for the drug[5].

Competitive Landscape

The rare disease market, while niche, is highly competitive due to the presence of other biologic drugs and the potential for biosimilars. However, KANUMA's unique mechanism of action and its approval for a specific rare condition help it maintain a strong market position. The entry of biosimilars in other therapeutic areas has shown that biologic drugs can experience price decreases and changes in market share, but KANUMA's rarity and specificity may shield it from immediate biosimilar competition[1].

Pricing and Reimbursement

Biologic drugs, including KANUMA, are often priced at a premium due to their complex manufacturing processes and the high cost of research and development. The pricing strategy for KANUMA is influenced by reimbursement policies, which vary by region. In markets with favorable reimbursement policies, such as the U.S., KANUMA can generate significant revenue. However, in regions with stricter pricing controls, revenue may be impacted[4].

Research and Development Expenses

Alexion Pharmaceuticals invests heavily in research and development (R&D) to support the ongoing development of KANUMA and other pipeline products. In 2020, Alexion's GAAP R&D expense was $1,002.9 million, and non-GAAP R&D expense was $929.4 million. These investments are crucial for maintaining market leadership and exploring new indications for KANUMA[5].

Sales and Marketing Expenses

Sales, General, and Administrative (SG&A) expenses are another significant component of Alexion's financials. In 2020, GAAP SG&A expenses were $1,399.9 million, and non-GAAP SG&A expenses were $1,198.6 million. These expenses reflect the company's efforts to promote KANUMA and other products, as well as to build and maintain a strong sales and marketing infrastructure[5].

Financial Highlights

  • Net Product Sales: $117.9 million in Q4 2020, a 5% increase from Q4 2019.
  • GAAP Cost of Sales: $553.5 million in 2020, compared to $394.5 million in 2019.
  • GAAP R&D Expense: $1,002.9 million in 2020, compared to $886.0 million in 2019.
  • GAAP SG&A Expense: $1,399.9 million in 2020, compared to $1,261.1 million in 2019[5].

Impact of Acquisitions and Mergers

In 2021, Alexion was acquired by AstraZeneca, which has significant implications for KANUMA's financial trajectory. AstraZeneca's strong financial position and global reach can enhance KANUMA's market access and patient reach. The acquisition also brings additional resources for R&D and marketing, potentially driving further growth for KANUMA[3].

Future Outlook

The future outlook for KANUMA is positive, driven by several factors:

  • Growing Demand: The increasing awareness and diagnosis of rare diseases like LAL-D are expected to drive demand for KANUMA.
  • Pipeline Expansion: AstraZeneca's robust pipeline and ongoing R&D efforts may lead to new indications or formulations of KANUMA.
  • Global Market Access: AstraZeneca's global presence can help expand KANUMA's reach into new markets.

Challenges

Despite the positive outlook, KANUMA faces several challenges:

  • Regulatory Environment: Changes in regulatory policies, especially regarding pricing and reimbursement, can impact KANUMA's revenue.
  • Competition: Although rare, the potential entry of biosimilars or new biologic drugs targeting LAL-D could challenge KANUMA's market position.
  • Economic Factors: Economic downturns or changes in healthcare policies can affect the affordability and accessibility of biologic drugs like KANUMA.

Key Takeaways

  • KANUMA is a biologic drug with a strong market position in the rare disease segment.
  • It has shown stable revenue growth since its launch.
  • The acquisition by AstraZeneca is expected to enhance its market reach and R&D capabilities.
  • Despite challenges, the future outlook for KANUMA remains positive due to growing demand and potential pipeline expansions.

FAQs

Q: What is KANUMA used for? A: KANUMA is used to treat lysosomal acid lipase deficiency (LAL-D), a rare genetic disorder.

Q: When was KANUMA approved by the FDA? A: KANUMA was approved by the FDA in December 2015.

Q: How has the acquisition by AstraZeneca impacted KANUMA? A: The acquisition has provided KANUMA with additional resources for R&D and marketing, potentially enhancing its market access and patient reach.

Q: What are the main challenges facing KANUMA in the market? A: KANUMA faces challenges such as regulatory changes, potential competition from biosimilars, and economic factors affecting affordability and accessibility.

Q: What is the projected future outlook for KANUMA? A: The future outlook for KANUMA is positive, driven by growing demand, potential pipeline expansions, and enhanced market access through AstraZeneca.

Sources

  1. Estimating the impact of biosimilar entry on prices and expenditures - Tandfonline
  2. Kane Biotech Announces Second Quarter 2024 Financial Results - Kane Biotech
  3. Full year and Q4 2022 results - AstraZeneca
  4. Biologics Market Size to Hit Around USD 1.37 Trillion By 2033 - Biospace
  5. Alexion Reports Fourth Quarter and Full Year 2020 Results - Alexion Pharmaceuticals

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.